Results of the REDUCE-IT REVASC study are shedding additional light on the cardiovascular benefits of icosapent ethyl (Vascepa).
Presented at the Society of Cardiovascular Angiography and Interventions (SCAI) 2020 Scientific Sessions, the latest prespecified analysis of the landmark REDUCE-IT trial outline the impact of icosapent ethyl on first revascularizations and a slew of revascularization subtypes.
|